This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -2,300% and 85.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 26.92% and 15.53%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More
by Zacks Equity Research
Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
by Zacks Equity Research
Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinum-sensitive ovarian cancer.
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -26.83% and 62.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 17.19% and 22.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
by Zacks Equity Research
Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.
Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?
by Zacks Equity Research
Here is how Aerie Pharmaceuticals (AERI) and Mersana Therapeutics, Inc. (MRSN) have performed compared to their sector so far this year.
Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
by Zacks Equity Research
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
by Zacks Equity Research
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Mersana Therapeutics, Inc. (MRSN)? Wall Street Analysts Think 256%
by Zacks Equity Research
The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -90.32% and 89.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Matches Q1 Earnings Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Sangamo (SGMO): Can Its 9.6% Jump Turn into More Strength?
by Zacks Equity Research
Sangamo (SGMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1.49% and 10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 59.55% and 931.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?
by Zacks Equity Research
Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.